Radium-223 was minimally myelosuppressive. Multivariate analyses of data from ALSYMPCA patients identified baseline factors that may increase hematologic toxicity risk with radium-223. Extent of disease and degree of prostate-specific antigen elevation were predictive of grade 2-4 anemia; prior docetaxel, and decreased hemoglobin and platelets were predictive of grade 2-4 thrombocytopenia. Patients with these factors should be closely monitored during radium-223 therapy. Background: Myelosuppression is common in patients with progressive castration-resistant prostate cancer and bone metastases. Radium-223 prolongs overall survival in these patients but may cause myelosuppression; understanding risk factors will improve clinical decision making. We describe hematologic safety of radium-223 in ALSYMPCA and post hoc analyses identifying patients at increased risk for hematologic toxicity. Patients and Methods: Hematologic parameters and adverse events were analyzed. Multivariate analyses assessing baseline risk factors for hematologic toxicities were performed separately for radium-223 and placebo patients. Results: Nine hundred one patients received radium-223 (n ¼ 600) or placebo (n ¼ 301); 65% of radium-223 and 48% of placebo patients had the full 6 cycles. Grade 3/4 thrombocytopenia was more common in radium-223 versus placebo patients (6% vs. 2%). Logistic regression analyses identified significant baseline predictors for grade 2-4 hematologic toxicities related to radium-223 treatment: extent of disease (6-20 vs. < 6 bone metastases; odds ratio [OR] ¼ 2.76; P ¼ .022) and elevated prostate-specific antigen (OR ¼ 1.65; P ¼ .006) for anemia; prior docetaxel (OR ¼ 2.16; P ¼ .035), decreased hemoglobin (OR ¼ 1.35; P ¼ .008), and decreased platelets (OR ¼ 1.44; P ¼ .030) for thrombocytopenia. Neutropenia events were too few in placebo patients for a comparative analysis. There were no significant associations between hematologic toxicities and number of radium-223 injections received (4-6 vs. 1-3). Conclusion: Radium-223 has a favorable safety profile with a low myelosuppression incidence. Understanding baseline factors associated with myelosuppression may assist clinicians in avoiding severe myelosuppression events with radium-223.
Introduction
More than 90% of men with metastatic castration-resistant prostate cancer (mCRPC) have bone metastases, 1 often with pain and bone fractures. [1] [2] [3] [4] Anemia accompanies advancing disease and is a risk factor for poor outcome in mCRPC. 5, 6 Docetaxel and cabazitaxel chemotherapy, particularly when given late in the course of the disease, may cause anemia. [7] [8] [9] Radium-223 may also cause anemia and thrombocytopenia, which can mimic or exist concurrently with bone marrow failure. Thus, the ability to identify potential risk factors for hematologic toxicity before radium-223 initiation is important, so high-risk patients can be monitored for treatment modifications. Radium-223 dichloride (radium-223), approved for patients with CRPC and symptomatic bone metastases, 10, 11 is a calcium mimetic binding to newly formed bone in areas of bone metastases. 12 The high linear energy transfer of emitted alpha particles causes predominantly nonrepairable double-stranded DNA breaks in tumor cells, [12] [13] [14] and the large size of the alpha particle results in a short path length and localized area of intense tissue destruction (< 100 mm; 2-10 cell diameters). Unlike beta particleeemitting radionuclides indicated for pain palliation, the short range of therapeutic radium-223 alpha particles spares distant hematologic tissue, which may result in fewer hematologic adverse events (AEs). 13 Early radium-223 experience indicated a low incidence of clinically significant myelosuppression with single injections of up to 250 kBq/ kg 15 weeks. 17 ALSYMPCA, a phase III, randomized, double-blind, placebocontrolled multinational study compared efficacy and safety of radium-223 plus best standard of care (BSoC) versus placebo plus BSoC in patients with CRPC and symptomatic bone metastases. Radium-223 significantly improved median overall survival by 3.6 months (hazard ratio [HR] ¼ 0.70; 95% confidence interval, 0.58-0.83; P < .001) versus placebo and showed favorable safety with low myelosuppression. 11, 18 Based on these results, radium-223 was approved for CRPC patients with symptomatic bone metastases and no visceral metastases. This report further examines radium-223 hematologic safety in ALSYMPCA, presenting all hematologic AEs with statistical comparisons of select hematologic AEs between treatment groups, detailed post hoc analyses identifying baseline factors that may increase risk for hematologic toxicity, and further characterization of patients who experienced grade 3 or 4 thrombocytopenia and pancytopenia or bone marrow failure.
Methods

Patients
ALSYMPCA trial design with full enrollment criteria has been reported. 11 Enrolled patients had symptomatic CRPC and ! 2 bone metastases with no visceral metastases, elevated and rising prostate-specific antigen (PSA) level, Eastern Cooperative Oncology Group performance status 2, life expectancy ! 6 months, and adequate baseline hematologic, renal, and liver function. Adequate hematologic function was defined as absolute neutrophil count ! 1.5 Â 10 9 /L, platelet count ! 100 Â 10 9 /L, and hemoglobin ! 10.0 g/dL. Patients either had previous docetaxel treatment or were unsuitable for or declined docetaxel. Patients must have had symptomatic disease, ie, requiring regular opioid or nonopioid analgesic use or having received external beam radiation therapy (EBRT) for bone pain within 12 weeks before randomization. Chemotherapy, blood transfusions, and erythropoietin stimulants were not permitted within 4 weeks of randomization; hemibody external radiotherapy and radiopharmaceuticals within 24 weeks were not allowed.
The trial was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent.
Study Design
Patients were randomized 2:1 to radium-223 50 kBq/kg (55 kBq/kg following the NIST update 16 ) plus BSoC or placebo plus BSoC every 4 weeks for 24 weeks (6 injections). BSoC was defined as routine care provided at each center and included EBRT for pain as indicated. Patients had received docetaxel or were not healthy enough to receive the drug, they declined it, or it was not available. Data were not collected on the number of previous docetaxel doses or the cumulative docetaxel dose received. Concomitant chemotherapy was not permitted during treatment. The primary end point was overall survival; safety was a secondary end point. The planned follow-up period was 3 years.
Assessments
Safety was assessed by incidence and severity of hematologic and nonhematologic treatment-emergent AEs, clinical chemistry, electrocardiogram, and physical examination; relationship to treatment was reported as judged by the investigator. All AEs occurring after randomization and within 12 weeks after the last study-drug injection were reported and evaluated for potential relationship to study drug. AEs were graded per Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Grade 3/4 thrombocytopenia was based on investigator's reporting of AEs, which included relevant symptoms, and not based solely on platelet laboratory values.
Blood samples for hematology were to be analyzed in the local laboratory and evaluated within 24 hours before each study-drug administration.
Statistical Analysis
Statistical methods used in ALSYMPCA have been described. 11, 19 Descriptive statistics (n, mean, standard deviation, minimum, median, and maximum values) were presented for clinical laboratory tests (hematology and clinical biochemistry) and their changes from baseline. Post hoc analyses of hematology data included time to first blood transfusion, patients with grade 3 or 4 thrombocytopenia, and patients with preferred term pancytopenia or bone marrow failure. Cox regression analysis was used to assess time to first blood transfusion. Grade 3/4 thrombocytopenia duration was assessed from time of initial recording to resolution, patient death, or close of study database. Fisher's exact test was used to compare hematologic AE rates for radium-223 versus placebo groups, and Wilcoxon rank sum test for differences in laboratory values between groups at different time points. Post hoc analyses of ALSYMPCA patients treated with radium-223 versus placebo were performed separately using logistic regression analysis to explore baseline risk factors for grade 2-4 hematologic toxicity; patients with grade 3/4 hematologic toxicity were too few for meaningful analysis. Baseline factors prespecified in ALSYMPCA, including additional baseline covariates based on clinical relevance to the hematologic toxicity, were used in the regression analysis. Baseline factors identified as significantly correlated with grade 2-4 anemia, neutropenia, and thrombocytopenia in the radium-223 subset, but not placebo subset, were considered likely to predict radium-223 treatment effect on AE occurrence. Analyses were performed in 3 steps. First, univariate logistic regression was performed for each potential risk factor. Second, variables with P < .10 in the univariate analysis were entered into the multivariate analysis. Baseline hemoglobin, neutrophils, and platelets were added even if univariate P was > .10, given that these factors are expected to correlate with respective hematologic AEs. Third, the model was subject to a stepwise procedure, the optimal model defined as that with the smallest Akaike information criteria (AIC) value. 20 Given the exploratory nature of the analysis, adjustments for multiple comparisons were not made. Statistical programming and analyses used SAS 9.2 (SAS Institute, Cary, NC) and R 3.0.1 (R Foundation for Statistical Computing, Vienna, Austria); analyses were based on safety population.
Results
Patients
ALSYMPCA intent-to-treat (ITT) population included 921 patients randomized to radium-223 plus BSoC or placebo plus BSoC. Safety population included 600 radium-223 and 301 placebo patients who received ! 1 study-drug injection (Figure 1 ). Baseline clinical and demographic characteristics were well balanced between groups (Table 1) ; 387/600 (65%) radium-223 and 145/301 (48%) placebo patients received all 6 study-drug injections (Supplemental Table 1 in the online version).
Dynamics of Hematologic Laboratory Values
Hemoglobin showed modest decreases in both treatment groups, persisting through follow-up; differences between radium-223 and placebo groups were significant only during follow-up (weeks 44, 51, 69). For radium-223 patients, median hemoglobin decreased from 12.2 g/dL at baseline to 11.4 g/dL at treatment end (week 24) and 10.8 g/dL at follow-up visit 2 (week 44). Among placebo patients, hemoglobin decreased from 12.1 g/dL at baseline to 11.6 g/ dL and 11.2 g/dL at weeks 24 and 44, respectively ( Figure 2A ). Median absolute neutrophil counts (ANCs) decreased modestly in radium-223 patients with some recovery during follow-up. ANC Safety of Radium-223 in CRPC remained constant for placebo patients, with little change from baseline. Significant differences versus placebo were observed over most of the treatment period: with radium-223, baseline was 4.5 Â 
Hematologic AEs
No significant differences existed between treatment groups in anemia rates for all grades (radium-223, 31%; placebo, 31%) or grade 3/4 (radium-223, 13%; placebo, 13%). Similarly, grade 3/4 neutropenia rates were not significantly different (radium-223, 2%; placebo, 1%), although significance was reached for all grades (radium-223, 5%; placebo, 1%; P ¼ .002). Thrombocytopenia rates reached significance for all-grade (radium-223, 12%; placebo, 6%; P ¼ .005) and grade 3/4 events (radium-223, 6%; placebo, 2%; P ¼ .005). One patient with grade 5 thrombocytopenia (15 Â 10 9 /L), believed related to radium-223, died from pneumonia with hypoxemia and no evidence of bleeding (Table 2) . Additional hematologic AEs observed in ! 1 patient with radium-223 treatment are shown in 
Blood Transfusions
Similar proportions of radium-223 (42%) and placebo (39%) patients required blood transfusions from randomization to study end. Platelets were more frequently administered to radium-223 patients (Table 3 ). There was no significant difference between radium-223 and placebo patients in time to first blood transfusion (HR ¼ 0.92; 95% confidence interval, 0.74-1.115; P ¼ .452) (Supplemental Figure 1 in the online version).
Analyses of Baseline Risk Factors for Grade 2-4 Hematologic AEs
Results from univariate and multivariate analyses for radium-223 and placebo patients are shown in Supplemental Tables 2-5 in the online version. Final optimal stepwise models for radium-223 and placebo patients are shown in Table 4 and Supplemental Table 6 in the online version, respectively. Some variables included in the univariate analysis, such as EBRT within 12 weeks of screening, did not reach significance (P < .10) as required for inclusion in the multivariate analysis and the stepwise model. 
Platelets, Â10 
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The risk-assessment model for grade 2-4 anemia included 169/ 567 (30%) radium-223 patients and 78/290 (27%) placebo patients with events (Table 4 and Supplemental Table 6 in the online version). Baseline factors significantly associated with increased risk for radium-223 patients were greater extent of disease (6-20 vs. < 6 metastases; odds ratio [OR] ¼ 2.76; P ¼ .022) and higher PSA (OR ¼ 1.65; P ¼ .006). Risk of grade 2-4 anemia was not statistically significant among those who received 4-6 versus 1-3 radium-223 injections (OR ¼ 1.57; P ¼ .097). Baseline factors that were significant in both radium-223 and placebo patients, and therefore not considered risk factors likely to predict radium-223 treatment effect on anemia occurrence, included extent of disease (> 20 vs. < 6 metastases), higher baseline total alkaline phosphatase, and lower baseline hemoglobin levels (Table 4 and Supplemental Table 6 in the online version).
The grade 2-4 neutropenia model included 24/591 (4%) radium-223 patients with events; too few placebo patients (3/301 [1%]) had events for comparative analysis to assess relationship with treatment effect. In radium-223 patients, risk for grade 2-4 neutropenia increased with prior docetaxel therapy (OR ¼ 3.44; P ¼ .020), World Health Organization (WHO) ladder cancer pain score (2 vs. 3) (OR ¼ 3.58; P ¼ .042), and decrease in baseline neutrophil counts (OR ¼ 2.01; P < .001). No significant association existed among radium-223 patients who received 4-6 versus 1-3 radium-223 injections (OR ¼ 1.14; P ¼ .837) ( Table 4) .
The grade 2-4 thrombocytopenia model included 53/573 (9%) radium-223 patients and 11/292 (4%) placebo patients with events (Table 4 and Supplemental Table 6 in the online version). The small number of events among placebo patients reduces confidence in results for this group. Prior docetaxel therapy (OR ¼ 2.16; Baseline factors that were significant in both radium-223 and placebo patients, and therefore not considered risk factors likely to predict radium-223 treatment effect on thrombocytopenia occurrence, included increased age and higher baseline PSA.
Patients With Grade 3 or 4 Thrombocytopenia
Compared with baseline characteristics of the ALSYMPCA safety population (Table 1) , the small group of 38 radium-223 and 6 placebo patients who developed grade 3/4 thrombocytopenia had a higher percentage with prior docetaxel (31/38 [82%] radium-223 and 5/6 [83%] placebo patients) (Supplemental Table 7 in the online version). Other apparent differences included more extensive disease (> 20 metastases or superscan) (23/38 [61%] radium-223 and 3/6 [50%] placebo patients) and higher baseline median PSA (344 mg/L for radium-223 and 1472 mg/L for placebo).
Platelet counts gradually decreased, reaching grade 3/4 at median 19 weeks (range 2.4-38 weeks) relative to first radium-223 injection ( Figure 3A) ; 28/38 patients (74%) received ! 4, and 13/38 (34%) received all 6 radium-223 injections. In 9/38 (24%) patients, platelet counts were ! 350 Â 10 9 /L at screening; more than half had ! 230 Â 10 9 /L. Patients with higher screening platelet counts (! 223 Â 10 9 /L) and rapid platelet decline during treatment tended to have more advanced disease (ALP ! 220 U/L), more bone pain, and more bone metastases (data not shown). Only 1/38 (3%) patient recovered to ! 150 Â 10 9 /L with no apparent relationship to screening platelet count. A similar pattern was seen for 6 placebo patients ( Figure 3B ) with no recovery during follow-up.
The majority of radium-223 patients with grade 3/4 thrombocytopenia (35/38 [92%]) had late onset, after at least the third injection, which may suggest a cumulative effect and mechanism different from that seen with placebo ( Figure 3C ).
Grade 3/4 thrombocytopenia duration was < 4 weeks for all 6/6 (100%) placebo patients and for 15/38 (39%) radium-223 patients. For 10/38 (26%) radium-223 patients, events had longer duration, 4 to 12 weeks; for 13/38 (34%) patients, duration was > 12 weeks ( Figure 3D ).
Treatment delays were seen in 16/38 (42%) radium-223 patients with grade 3/4 thrombocytopenia; AEs were the most common reason (14 patients), including anemia (n ¼ 5), thrombocytopenia (n ¼ 2), neutropenia (n ¼ 1), and other AE-related reasons (n ¼ 6). Despite treatment delays due to AEs, 6/14 (43%) radium-223 patients completed all 6 injections, including both patients with delay due to grade 3/4 thrombocytopenia.
Pancytopenia or Bone Marrow Failure
Pancytopenia was reported for 12/600 (2%) radium-223 patients and bone marrow failure for 1/600 (< 1%) radium-223 and no placebo patients. Among 13 radium-223 patients with pancytopenia or bone marrow failure, 5/13 (39%) did not complete all 6 study injections. These 13 patients, versus overall ITT population (Supplemental Table 8 in the online version), show a higher proportion with prior docetaxel exposure (85% vs. 57% respectively) and higher baseline PSA values (344 mg/L vs. 146 mg/L, respectively).
Discussion
Radium-223 is well tolerated with minimal myelotoxicity in patients with CRPC and bone metastases, 11, 15, 17, 18 comparing well in safety and efficacy with other therapies for these patients. One patient had both a missing and grade 3 AE grade level and is included in N (%). Within a MedDRA system organ class and preferred term, a missing Common Terminology Criteria (CTC) grade is taken as the "worst" case unless the nonmissing CTC grade is 5; then the maximum toxicity is CTC grade 5.
c P values were calculated from Fisher's exact tests comparing the AE rates between radium-223 and placebo groups.
Although there were no significant associations between hematologic toxicities and number of radium-223 injections received, it is important to note that patients were supported with transfusions as needed and as described in the prescribing information. 10 A high rate of anemia in patients with CRPC and bone metastases has been reported. 5, 6 In ALSYMPCA, anemia was the most common hematologic toxicity; its frequency and severity were the same with radium-223 and placebo and likely due to disease burden, although concomitant BSoC treatment effects were not accounted for. Median baseline values for hemoglobin (z12 g/dL) suggest that many or most patients were anemic at study entry, and logistic regression analysis showed correlations between grade 2-4 anemia and factors related to extent of disease (eg, elevated PSA and higher extent of disease) in radium-223 patients. Current prescribing information recommends that hemoglobin be ! 10 g/dL prior to first radium-223 administration. Ongoing protocols allow hemoglobin ! 8 g/dL (with transfusions). Neutropenia was more common in radium-223 patients. Neutrophil counts decreased with radium-223 treatment, but grade 3/4 events were rare and too few with placebo for comparison to assess the relationship with treatment effect in the logistic regression analysis.
Thrombocytopenia was more common in radium-223 patients, and risk increased with prior docetaxel and decreased baseline hemoglobin and platelets. Its association with prior docetaxel use is consistent with earlier analysis of ALSYMPCA patients showing a 3-fold greater incidence of grade 3/4 thrombocytopenia among radium-223 patients previously exposed to docetaxel versus those not exposed (9% vs. 3%). 25 Prudent management requires blood count evaluation before each radium-223 dose, with minimum values defined as a threshold for continued treatment, per current prescribing information (Supplemental Table 9 in the online version). 10 Prior to the first injection, ANC should be ! 1.5 Â 10 9 /L and platelets should be ! 100 Â 10 9 /L. Prior to each subsequent injection, ANC should be ! 1.0 Â 10 9 /L and platelets should be ! 50 Â 10 9 /L. If there is no recovery to these values within 6 to 8 weeks after the last injection despite supportive care, radium-223 should be discontinued.
No differences between radium-223 and placebo groups exists in frequency of blood transfusions or time to first blood transfusion, a finding that is noteworthy in this mCRPC population.
Clinicians are advised to balance benefit and risk when determining whether to continue treatment. It is acceptable to delay treatment; delays allowing completion of 6 radium-223 cycles may be key to ensuring maximum treatment benefit. It is important to note that thrombocytopenia onset was slow and did not warrant abrupt discontinuation of radium-223, and that number of radium-223 doses was not a risk factor in thrombocytopenia development.
Current treatment guidelines for CRPC and bone metastases recommend radium-223 as a first-line option in predocetaxel and postdocetaxel settings. [26] [27] [28] [29] Analysis of outcomes for ALSYMPCA patients who received chemotherapy (w70% of which was docetaxel) after completing the study-drug regimen (radium-223 or placebo) identified no new hematologic concerns and no Table 3 252 (41) 26 (4) 6 (1) 137 (22) 136 (22) 6 (1) 3 (1) 195 (32) 189 (31) 22 (4) 4 (1) Placebo (n ¼ 307)
(39)
118 (38) 2 (1) 2 (1) 69 (23) 68 (22) 0 2 (1) 80 (26) 80 (26) 2 ( End of study refers to when the patient is withdrawn, died, or completed the 3-year follow-up visit.
c End of treatment was defined as 4 weeks after the last study-drug injection.
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Clinical Genitourinary Cancer February 2017 -49 detrimental effects of prior radium-223 on overall survival. 30 Given these findings and those of current analyses regarding the relationship of radium-223 and prior docetaxel exposure to thrombocytopenia development, it may be prudent to consider radium-223 prior to docetaxel, although close monitoring of hematologic parameters may be required for patients who receive chemotherapy later in the treatment sequence.
Conclusion
Hematologic AEs are manageable if recognized early and handled with appropriate care, generally allowing continued treatment for maximum benefit. These ALSYMPCA data provide guidance to clinicians and help place their clinical experience with radium-223 into a broader context. Following recommendations in the prescribing information, 10 with insights from the current analysis, may enhance appropriate patient management and safety.
Clinical Practice Points
In the phase III ALSYMPCA trial, radium-223 significantly improved overall survival and delayed time to first symptomatic skeletal event with a favorable safety profile, leading to its approval for the treatment of patients with CRPC and symptomatic bone metastases and no visceral metastases Overall, radium-223 was well tolerated and had a favorable hematologic safety profile with a low incidence of myelosuppression Post hoc analyses identified baseline risk factors associated with hematologic toxicities related to radium-223 treatment; prior docetaxel therapy and decreased platelet and hemoglobin levels were risk factors for grade 2-4 thrombocytopenia, and baseline extent of disease (6-20 vs. < 6 bone metastases) and elevated PSA were risk factors for grade 2-4 anemia; neutropenia events in placebo patients were too few for a comparative analysis to assess a relationship with treatment effect Based on a logistic regression model. Odds ratios of > 1 represent an increase in risk associated with an increase in baseline variable. Odds ratios are relative risk for 1 unit increase in baseline variable (for those without log transformation) or a 10-times increase (for those with log transformation). Abbreviations: N ¼ number of radium-223 and placebo patients included in the model; PSA ¼ prostate-specific antigen; tALP ¼ total alkaline phosphatase; WHO ¼ World Health Organization. a Relative increase in risk for an adverse event with respect to an increase in age of 1 year. b Superscan refers to a bone scan showing diffuse, intense skeletal uptake of the tracer without renal and background activity. Safety of Radium-223 in CRPC Disclosure N.J.V. has served as a consultant for Bayer, Genentech, Exelexis, Medivation, and Pfizer, and has served on speakers bureaus for BMS, Pfizer, Genentech, Novartis, Sanofi Aventis, Dendreon, and Bayer. R.E.C. has received grants or funding to his institution from Bayer, Amgen, and Celgene. J.M.M. has no conflicts of interest to disclose. S.N. has served as a consultant or advisor for Bayer. J.M.O. has received grants or funding from Bayer and has served as a consultant or advisor for and on the speakers bureaus for Astellas, Bayer, Sanofi, and Janssen. C.P. has received grants or funding from Bayer and honoraria from Bayer and Janssen. A.W. has received honoraria from and served as a consultant or advisor for Sanofi, Astellas, EXINI, and Roche, and has received travel, accommodations, or expenses from Sanofi and Astellas. M.T. has served as a consultant or advisor for Bayer. L.X. and J.G. are employed by Bayer HealthCare Pharmaceuticals. O.S. has received grants or funding from, served as a consultant or advisor for, and received honoraria from Bayer.
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